Fig. 5
Validation of three IMLs in the isolation of CTCs from patients with pediatric brain tumors. (A-D): Representative fluorescence in cells isolated by GFAP-IMLs from patients’ peripheral blood. Isolated cells were labeled with an anti-GFAP monoclonal antibody conjugate by FITC (scale bar: 20 μm); (E–H): Representative fluorescence in cells isolated by GFAP-IMLs from patients’ CSF. Isolated cells were labeled with an anti-GFAP monoclonal antibody conjugate by FITC (scale bar: 20 μm)